Vaccine specialist Moderna (MRNA) reported its fiscal Q3 2020 financial results Thursday morning. Let’s run down the basic financial news first, and turn to the vaccine that everyone really wants to hear about: Q3 was kind of a weird quarter for Moderna from a financial perspective. On the one hand, an explosion in grant revenue tied to the COVID-19 pandemic sent revenues soaring 830% to $157.9 million. On the other hand, though, expenses soared as well — up 166% to $393 million.And because $393 million is more than $157.9 million Moderna lost money.A lot of money.$0.59 per share to be …read more
Source:: Yahoo Finance
